Bli medlem
Bli medlem

Du är här


Navamedic ASA: Navamedic ASA appoints new CEO

Tom Rönnlund has been appointed new CEO of Navamedic ASA. Mr Rönnlund brings
more than 17 years of business development and general management experience
from the international healthcare industry to Navamedic.

Tom Rönnlund joins Navamedic from IMS Health Inc, a global analytics and
technology services company focused on the healthcare sector, where he held
the position of General Manager for the Nordic&Baltic Region. Prior to
joining IMS Health, Tom has served in sales, marketing and general management
roles with biopharmaceutical companies such as Bristol-Myers Squibb and Eli
Lilly. He holds a degree in Business Administration and Economics from
Stockholm University.

Tom Rönnlund assumes his new responsibilities at Navamedic on 18 May 2015.

"We are pleased that we have succeeded in recruiting Tom Rönnlund to
Navamedic. He brings with him vast industry experience from Nordic and
international markets and an impressive track record of business growth and
general managemet. I am confident he will succeed in reinforcing the positive
revenue and profit development the company is experiencing together with the
Navamedic team. We thank Håkan Josephsson, who remains with the company, for
his invaluable support as interim CEO" Navamedic Chairman Johan Reinsli said.

"I am very excited to join Navamedic and am looking forward to build on the
great work by the current management team in focusing the product portfolio
for continued growth and improved profitability as well as actively pursue
portfolio expansion through partnerships and potential acquisitions" says Tom

For further information, please contact Navamedic's Chairman Johan Reinsli,
telephone +47 91604145 or Tom Rönnlund, appointed CEO, telephone +46 768 564

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and
distributing more than 120 products in the Nordic and Benelux markets. The
Company operates three business areas; Pharma Products, Medical Nutrition and
Consumer Care based on its relationship with a number of pharmaceutical
product manufacturers. Navamedic is listed on the Oslo Stock Exchange
(ticker: NAVA).

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Navamedic ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.